- Home
- BXP vs RPRX Comparison
BXP vs RPRX Comparison
Compare BXP & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXP
- RPRX
- Stock Information
- Founded
- BXP 1970
- RPRX 1996
- Country
- BXP United States
- RPRX United States
- Employees
- BXP N/A
- RPRX N/A
- Industry
- BXP Real Estate Investment Trusts
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- BXP Real Estate
- RPRX Health Care
- Exchange
- BXP Nasdaq
- RPRX Nasdaq
- Market Cap
- BXP 13.1B
- RPRX 11.8B
- IPO Year
- BXP 1997
- RPRX 2020
- Fundamental
- Price
- BXP $80.66
- RPRX $26.43
- Analyst Decision
- BXP Buy
- RPRX Strong Buy
- Analyst Count
- BXP 14
- RPRX 6
- Target Price
- BXP $80.64
- RPRX $41.67
- AVG Volume (30 Days)
- BXP 1.3M
- RPRX 3.1M
- Earning Date
- BXP 10-29-2024
- RPRX 11-06-2024
- Dividend Yield
- BXP 4.87%
- RPRX 3.18%
- EPS Growth
- BXP 87.61
- RPRX 518.56
- EPS
- BXP 2.30
- RPRX 2.55
- Revenue
- BXP $3,344,005,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- BXP N/A
- RPRX $12.38
- Revenue Next Year
- BXP $1.56
- RPRX $11.26
- P/E Ratio
- BXP $35.13
- RPRX $10.35
- Revenue Growth
- BXP 4.47
- RPRX N/A
- 52 Week Low
- BXP $52.61
- RPRX $25.10
- 52 Week High
- BXP $90.11
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- BXP 47.64
- RPRX 45.67
- Support Level
- BXP $77.28
- RPRX $25.47
- Resistance Level
- BXP $79.76
- RPRX $26.67
- Average True Range (ATR)
- BXP 2.14
- RPRX 0.64
- MACD
- BXP -0.11
- RPRX 0.05
- Stochastic Oscillator
- BXP 50.67
- RPRX 40.80
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.